The coagulation and fibrinolytic systems are linked by the thrombin-thrombomodulin complex which regulates each system through activation of protein C and TAFI, respectively. We have used novel assays and techniques to study the enzymology and biochemistry of TAFI and TAFIa, to measure TAFI activation in hemophilia A and protein C deficiency and to determine if enhancing TAFI activation can improve hemostasis in hemophilic plasma and whole blood. We show that TAFIa not TAFI attenuates fibrinolysis in vitro and this is supported by a relatively high catalytic efficiency (16.41μM-1s-1) of plasminogen binding site removal from fibrin degradation products (FDPs) by TAFIa. Since the catalytic efficiency of TAFIa in removing these sites is ~60-fold higher than that for inflammatory mediators such as bradykinin it is likely that FDPs are a physiological substrate of TAFIa. The high catalytic efficiency is primarily a result of a low Km which can be explained by a novel mechanism where TAFIa forms a binary complex with plasminogen and is recruited to the surface of FDPs. The low Km also suggests that TAFIa would effectively cleave lysines from FDPs during the early stages of fibrinolysis (i.e. at low concentrations of FDPs). Since individuals with hemophilia suffer from premature fibrinolysis as a result of insufficient TAFI activation we quantified TAFI activation in whole blood from hemophilic subjects. Both the rate of activation and the area under the TAFI activation time course (termed TAFIa potential) was determined to be reduced in hemophilia A and the TAFIa potential was significantly and inversely correlated with the clinical bleeding iii phenotype. Using a novel therapeutic strategy, we used soluble thrombomodulin to increase TAFI activation which improved the clot lysis time in factor VIII deficient human plasma and hemophilic dog plasma as well as hemophilic dog blood. Finally, we briefly show in a biochemical case study that TAFI activation is enhanced in protein C deficiency and when afflicted individuals are placed on Warfarin anticoagulant therapy, TAFI activation is reduced. Since TAFIa stabilizes blood clots, this suggests that reducing TAFI activation or inhibiting TAFIa may help restore blood flow in vessels with pathological thrombosis. / Thesis (Ph.D, Biochemistry) -- Queen's University, 2010-09-23 10:12:18.892

No description available.

No description available.

No description available.

English Abstract Glutamate carboxypeptidase II (GCPII) is a membrane metallopeptidase expressed in many human tissues, predominantly in prostate, brain and small intestine. In brain it cleaves the most abundant peptide neurotransmitter N-acetyl-L-aspartyl-α-L-glutamate into N-acetyl-L-aspartate and free L-glutamate. Thus, GCPII participates in glutamate excitotoxicity through the release of free glutamate into the synaptic cleft. Inhibition of this activity has been shown to be neuroprotective in rats. In the human jejunal brush border, GCPII cleaves off terminal glutamate moieties from poly-γ-glutamylated folates, which can be then transported across the intestinal mucosa. The function of GCPII in human prostate is unknown but it is overexpressed in prostate cancer. Therefore, GCPII is an important marker of prostate cancer and its progression.Moreover, it could become a perspective target for treatment of prostate cancer as well as neuronal disorders associated with glutamate excitotoxicity. For the development and testing of novel drugs and therapeutics it is necessary to have an appropriate animal model. Mouse (Mus musculus) is such a model and it is widely used by many experimentators. However, no detailed comparison of mouse and human GCPII orthologs regarding their enzymatic activity, inhibition...

Developing microbial systems capable of converting low cost lipids into value added products depends on the ability to acquire substrates from the growth media. Saccharomyces cerevisiae can acquire free fatty acids from the growth media and a portion of these lipids can be converted into new lipid products. However, they cannot acquire complex lipids from the growth media unless a nonspecific lipase is included. To circumvent lipase addition, we are genetically engineering S. cerevisiae to secrete a lipase into the growth media. We selected the LIP2 gene from Yarrowia lipolytica, which encodes a nonspecific lipase. Several modifications were made to the LIP2 gene to improve processing. Results identified strains secreting the most lipase. From these results, high producing strains were inserted into an oil inducible vector. Halo assays confirmed lipase secretion, while measuring the fatty acid composition confirmed triacylglycerol breakdown, and yeast uptake of the free fatty acids released.

A esquistossomose representa um grande problema de saúde pública em regiões tropicais, negligenciado pelas empresas farmacêuticas. Três genes foram selecionados a partir do transcriptoma do S. mansoni para serem caracterizados molecularmente e testados como vacinas. O gene da Carboxipeptidase apresentou altos níveis de transcrição no estágio de cercária e uma variável expressão protéica nos estágios intra-hospedeiros. A proteína recombinante renaturada apresentou baixa atividade. O gene da Esfingomielinase apresentou alto nível transcricional em ovos, sendo expresso em todos os estágios exceto em esquistossômulos de 7 dias e fêmeas. O gene da Fosfatase Alcalina apresentou elevada transcrição em cercária, mas a expressão da proteína se eleva somente no estágio de esquistossômulo. A imunização de camundongos com cada uma das três proteínas recombinantes expressas em E. coli não levou à redução da carga parasitária após desafio. Estes resultados demonstram que diversas características de um antígeno são necessárias para que este seja um bom candidato vacinal. / Schistosomiasis is a major public health problem in tropical areas and neglected by most of the pharmaceutical companies. Three genes were selected from S. mansoni transcriptome to be molecularly characterized and tested as vaccines. The Carboxypeptidase gene showed high transcription levels in cercariae stage and a variable protein expression in intra-host stages. The refolded recombinant protein showed limited activity. The Sphingomyelinase gene showed the highest level of transcriptional activity in the egg stage and the protein is expressed in all stages but 7-day old schistosomula and females. The Alkaline Phosphatase gene showed a high transcriptional activity in cercariae stage with most of the mRNA being translated into protein as soon as it penetrates its definitive host. Immunization of mice with each of the three proteins did not show reduction in worm burden recovery after challenge. These results demonstrate that several characteristics of an antigen are important for it to be considered a good vaccine candidate.

A esquistossomose representa um grande problema de saúde pública em regiões tropicais, negligenciado pelas empresas farmacêuticas. Três genes foram selecionados a partir do transcriptoma do S. mansoni para serem caracterizados molecularmente e testados como vacinas. O gene da Carboxipeptidase apresentou altos níveis de transcrição no estágio de cercária e uma variável expressão protéica nos estágios intra-hospedeiros. A proteína recombinante renaturada apresentou baixa atividade. O gene da Esfingomielinase apresentou alto nível transcricional em ovos, sendo expresso em todos os estágios exceto em esquistossômulos de 7 dias e fêmeas. O gene da Fosfatase Alcalina apresentou elevada transcrição em cercária, mas a expressão da proteína se eleva somente no estágio de esquistossômulo. A imunização de camundongos com cada uma das três proteínas recombinantes expressas em E. coli não levou à redução da carga parasitária após desafio. Estes resultados demonstram que diversas características de um antígeno são necessárias para que este seja um bom candidato vacinal. / Schistosomiasis is a major public health problem in tropical areas and neglected by most of the pharmaceutical companies. Three genes were selected from S. mansoni transcriptome to be molecularly characterized and tested as vaccines. The Carboxypeptidase gene showed high transcription levels in cercariae stage and a variable protein expression in intra-host stages. The refolded recombinant protein showed limited activity. The Sphingomyelinase gene showed the highest level of transcriptional activity in the egg stage and the protein is expressed in all stages but 7-day old schistosomula and females. The Alkaline Phosphatase gene showed a high transcriptional activity in cercariae stage with most of the mRNA being translated into protein as soon as it penetrates its definitive host. Immunization of mice with each of the three proteins did not show reduction in worm burden recovery after challenge. These results demonstrate that several characteristics of an antigen are important for it to be considered a good vaccine candidate.

Mes travaux de thèse portent sur deux gènes cpbAg1 et cpbAg2 qui codent des enzymes digestives : les carboxypeptidases digestives du moustique Anopheles gambiae, vecteur majeur africain de Plasmodium falciparum, parasite responsable des formes graves du paludisme. La contribution de CPBAg1 dans le développement de P. falciparum chez An. gambiae a été démontrée ainsi qu'un rôle potentiel dans la production des oeufs du moustique (Lavazec et al., 2005 & 2007). Cependant le rôle potentiel de CPBAg2 dans ces deux phénotypes n'avait pas été abordé. Nos travaux ont permis de montrer des propriétés enzymatiques différentes pour chaque carboxypeptidase, avec CPBAg1 qui libère de l'arginine et de la lysine tandis que CPBAg2 est spécifique de l'arginine. La cinétique d'apparition in vivo des protéines montre une production précoce de CPBAg1 et une production constante de CPBAg2 au cours du processus de digestion du repas sanguin. L'analyse fonctionnelle de CPBAg1 et CPBAg2 utilisant l'inactivation génique par ARN interférence a permis de comprendre leurs rôles respectifs. Ainsi, CPBAg1 est impliquée dans le développement de P.falciparum chez An. gambiae, suggérant une plus forte dépendance du parasite pour les ressources en lysine. A l'inverse, CPBAg2 intervient au cours de la vitellogénèse du moustique et son inactivation induit également un retard du développement ovarien. Ainsi, ce dernier semble être plus dépendant de l'arginine, produit principalement par CPBAg2. CPBAg1 et CPBAg2 pourraient de ce fait être utilisées comme les cibles de nouvelles stratégies pour diminuer la transmission du paludisme, en bloquant le parasite chez le moustique tout en diminuant la production d'oeufs.

No description available.